Richard Schumacher is no stranger to successful start-ups. The Pressure BioSciences founder, president and CEO had a hand in five early-stage life science ventures, including Boston Biomedica.
Research & Development
The agreement calls for Cambridge, Mass.-based Perceptive, which is the clinical trial data management arm of Parexel International Corp., to use Sudbury, Mass.-based Optasia’s KneeAnalyzer software to enhance image analysis of the knee in osteoarthritis patients.
Parexel International Corp. ended the year on a down note, taking a $12 million tax adjustment to its bottom line, which combined with slow sales for a 76 percent drop in profits for the three months ended June 30.
The Waltham-based contract research organization reported $6.2 million in net income on $292 million in sales for the quarter, compared to $25 million on $332 million in sales for the same period last year.
For the full year, the company reported a $39 million on profit on $1.2 billion in sales, compared to $65 million on $1.1 billion in sales last year.
Charles River Laboratories International Inc. said it plans to acquire a provider of automated digital imaging software and also announced a strategic partnership with a venture capital firm that could add nearly four dozen early-stage pharmaceutical and biotech companies as contract research clients.
Other deals also may be on the way, as the Wilmington, Mass.-based contract research firm filed a shelf registration late Tuesday to sell stock and other securities. Proceeds would be intended for “general corporate purposes, including including working capital, acquisitions and retirement of debt,” the company said.
Caliper Life Sciences Inc. posted second-quarter sales of $32.1 million, down 5.6 percent compared with $34 million during the same period last year.
But increased consumable sales, reduced inventory and cost-cutting measures brought the Hopkinton, Mass.-based lab equipment and services provider closer to breaking even. Caliper posted a net loss of $4.1 million on the three months ended June 30, compared with a net loss of $6.7 million during the second quarter of 2008, a 39.3 percent reduction.
President Barack Obama tapped Francis Collins, the discoverer of the genes that cause such pernicious afflictions as cystic fibrosis and Huntington’s disease, to lead the National Institutes of Health, the Los Angeles Times reported.
Collins, 59, also led the government project to map the human genome, authored a best-seller detailing scientific reasons to believe in a higher power and is a widely respected research scientist.
If confirmed — as is expected, the newspaper reported — Collins would step into one of the most powerful positions in science, commanding 27 institutes and a $30 billion annual budget.
A bill re-authorizing the Small Business Administration’s seed grant program for start-ups, which significantly boosts the amount of the awards but decreases their number (and allows venture capital backing of grantees) passed 386-41 in the U.S. House of Representatives yesterday.
The bill, HR 2965, would increase the amount of Phase 1 Small Business Innovation Research grants to $250,000 and push SBIR Phase 2 grants to $2 million (Phase 1 grants are now $100,000; Phase 2 grants are $750,000).
Charles River Laboratories International Inc. is making a raft of changes to its two main divisions, research models and services and preclinical services, and to its sales force.
The Wilmington contract research provider said RMS president Real Renaud will retire by the end of 2010 after 45 years with the firm. He’ll be replaced by Davide Molho, who’ll be promoted from his job running the company’s European RMS operation.
The changes to Charles River Labs’ PCS business, aimed at streamlining its operations, will see its senior management taking on new responsibilities.
Chase Sebor faced the audience and spread his arms wide like a hockey goalie.
“You’re out in front of the goal and you just want the puck to hit you,” he said, eliciting laughter.
The demonstration wasn’t just comic relief. Sebor, the co-founder of Venture Technologies in North Billerica, was making a point about medical device failure. Errors, he said, are treasures.
“You want to detect them, detect them, detect them,” he said. “You want a culture, in the engineering process, in which you celebrate errors.”
That brought him to the hockey analogy (a friend is a goalie).
The Massachusetts Medical Device Development Center (M2D2) at UMass-Lowell doled out a quartet of $50,000 matching “Fast Lane” grants to early-stage medical device companies.
It’s the latest round of grants from the center, which aims to help young startups commercialize their products.
Travis Lau, a third-year resident at Tufts Medical Center, landed one of the grants to develop a hand-held safety suturing device aimed at reducing the risk of accidental needlesticks by healthcare professionals.
Caliper Life Sciences Inc. posted first-quarter sales of $28.5 million, down 2.8 percent compared with $29.3 million during the same period last year.
The Hopkinton contract research organization said the comparison includes $2.9 million in revenues from divested product lines during the 2008 first quarter; absent those revenues, sales rose nearly 8 percent.